Focus: Treeline Biosciences is a public oncology-focused biotech company headquartered in San Diego, specializing in difficult-to-drug molecular targets with validated biology.
Profile data last refreshed 15h ago · AI intelligence enriched 3w ago
Growing — net +7 jobs in 30d
8 jobs added vs 1 removed. Steady team buildout.
Treeline is a lean, early-stage oncology player suited to those seeking high-risk/high-reward exposure to difficult targets, but with minimal safety net for traditional career progression.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Treeline Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Treeline Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Standard BioTools to merge with Treeline in biotech transformation deal - The Pharma Letter
Standard BioTools to merge with Treeline in biotech transformation deal The Pharma Letter
Stealthy startup Treeline plans a reverse merger - BioPharma Dive
Stealthy startup Treeline plans a reverse merger BioPharma Dive
Novo underwhelmed by drug it once fought Pfizer for - STAT
Novo underwhelmed by drug it once fought Pfizer for STAT
Treeline merges with Standard, nabs lengthy cash runway for growing pipeline - FirstWord PHARMA
Treeline merges with Standard, nabs lengthy cash runway for growing pipeline FirstWord PHARMA
Standard BioTools and Treeline Biosciences Announce Merger Agreement - GlobeNewswire
Standard BioTools and Treeline Biosciences Announce Merger Agreement GlobeNewswire
8-K Filing: STANDARD BIOTOOLS INC. (LAB) (CIK 0001162194) — EXHIBIT 99.1
EXHIBIT 99.1
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Application of modelling of cell monolayer permeation data to generate input parameters compatible with in vitro-in vivo translation of blood-brain-barrier disposition of drugs.
UDP-Glucuronosyl transferase mediated drug-drug interactions: An Industry perspective on recommended in vitro studies.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo